<DOC>
	<DOCNO>NCT02470858</DOCNO>
	<brief_summary>The study design test hypothesis addition protease inhibitor dual NS5a-NS5B nucleoside prodrug analog enhance antiviral efficacy hence shorten treatment duration 3 week .</brief_summary>
	<brief_title>Triple DAAs Regimen Treating Non-cirrhotic HCV GT1b Subjects</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Age equal great 18 year , chronic genotype 1b HCV infection ; HCV RNA level &gt; 10,000 &lt; 10,000,000 IU/ml Screening ; Rapid response triple DAAs therapy le 500 IU/ml plasma HCV RNA level Day 2 ; No evidence cirrhosis . Cirrhosis define 1 following , within 6 month study entry : 1 . Liver biopsy show cirrhosis ; 2 . Fibroscan show cirrhosis result &gt; 12.5 kPa ; 3 . FibroTest® score &gt; 0.75 aspartate aminotransferase ( AST ) : platelet ratio index ( APRI ) &gt; 2 screening . Pregnant nursing female male pregnant female partner ; HIV chronic hepatitis B virus ( HBV ) infection ; Hematologic biochemical parameter Screening outside protocolspecified requirement ; Active recent history ( ≤ 1 year ) drug alcohol abuse ; Hepatocellular carcinoma malignancy ( exception certain resolve skin cancer ) ; History current evidence condition , therapy , laboratory abnormality circumstance might confound result study , interfere subject 's participation full duration study , best interest subject participate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>